Trial
NCT03839355
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
Pfizer; Bristol-Myers Squibb
Condition
Atrial Fibrillation
Intervention
Apixaban
Why stopped
Study terminated due to slower than anticipated enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-16